Aradigm Corp. (ARDM) Submits NDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Tweet Send to a Friend
Aradigm Corporation (NASDAQ: ARDM) (the “Company”) today announced it has submitted its New Drug Application (NDA) to the U.S. Food ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
